LGD-4033 (Ligandrol) 10mg is a selective androgen receptor modulator (SARM) oral compound supplied in a 50 tablet pack. Manufactured for consistent potency, stability, and research applications.
Format50 Tablets
Concentration10mg
Pay with Interac e-Transfer or Crypto
HPLC verified. COA on file for this batch
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
LGD-4033 (Ligandrol) is one of the most extensively researched SARMs in clinical and preclinical literature, having progressed through Phase I and Phase II human trials examining muscle wasting and sarcopenia. F40 Biotech’s formulation delivers 10mg per tablet in a 50 count bottle format, the same concentration as CSD’s generic 3×15 blister pack listing, with bottle packaging and manufacturer representing the primary differentiating variables between the two.
The bottle format provides a single continuous 50 tablet supply rather than the segmented blister pack presentation, suited to researchers who prefer bulk bottle storage over individually sealed blister units. LGD-4033’s core pharmacological profile remains consistent across both listings. Tissue selective non steroidal androgen receptor binding avoiding 5-alpha reductase and aromatase interaction, documented dose dependent lean body mass increases with measurable HPG axis suppression at higher research doses, and an approximately 24–36 hour half-life supporting once daily administration.
F40 Biotech formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range, each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD stocks LGD-4033 across both blister pack and bottle formats, giving researchers packaging preference flexibility within the same compound from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Store in a cool, dry place away from direct light and heat. Intended for research purposes only.
Commonly researched alongside other SARM compounds and PCT agents in comparative androgen receptor selectivity studies. Browse CSD’s full SARM range for complete sourcing.
LGD-4033 (Ligandrol) is a high affinity, orally bioavailable selective androgen receptor modulator originally developed by Ligand Pharmaceuticals and subsequently researched by Viking Therapeutics. It completed Phase I clinical trials demonstrating dose dependent lean mass increases and dose dependent HPG axis suppression. Making it one of the most clinically validated SARMs available. LGD-4033 is studied for lean mass accretion, strength enhancement, bone density improvement, and muscle wasting research. It is one of the most potent SARMs in terms of lean mass gains per milligram, producing meaningful anabolic effects at doses as low as 1mg daily in clinical research, with common performance research doses ranging from 5–10mg daily.
The active compound and dose are identical, LGD-4033 at 10mg per unit. The difference is packaging format. The 50 tablet bottle provides a larger total quantity. 500mg versus 450mg in the blister pack format in a single convenient container. The bottle format is more practical for researchers who prefer loose tablet storage and straightforward daily dispensing, while the blister pack format provides individual dose protection and convenient daily tracking. The 50 tablet bottle provides sufficient compound for a complete 50 day research cycle at once daily 10mg dosing.
LGD-4033 has a half-life of 24–36 hours, once daily administration is sufficient to maintain stable plasma Ligandrol levels throughout a research protocol. Common research doses range from 5–10mg daily; a single 10mg tablet covers the standard upper research dose range. The 50 tablet pack provides 500mg total. Sufficient for a complete 50 day research cycle at once daily 10mg dosing, covering a standard 6–8 week LGD-4033 protocol with buffer for dose assessment and taper if desired.
Yes! LGD-4033 produces the most significant HPG axis suppression of any commonly researched SARM, with dose dependent reductions in LH, FSH, and total testosterone observed in Phase I clinical trials. At 10mg daily for 3 weeks, testosterone suppression was measurable and meaningful in research subjects. A SERM based PCT protocol; typically Nolvadex 20–40mg daily for 4 weeks is strongly recommended following LGD-4033 research cycles of 6 weeks or longer at 10mg daily. Blood work before and after the research cycle is essential to assess suppression degree and guide PCT decisions.
Yes! This batch has been independently HPLC tested by an accredited third party laboratory confirming concentration accuracy at 10mg per tablet and compound identity as LGD-4033 (Ligandrol). A certificate of analysis is available.
